Primary effusion lymphoma: the decisions you may face

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

1. Is Histopathology & immunohistochemistry the only reasonable path for me, or is there a trial, a different sequence or a wait-and-see option?
   Why: A single standard does not mean a single choice; timing and trials are decisions too.
2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
   Why: The aim shapes how much side effect and disruption is worth accepting.
3. What happens if I delay, or decline this step for now? Is the decision reversible?
   Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
4. Does your recommendation follow the current guideline (WHO Classification of Haematolymphoid Tumours, 5th edition (2022), with the International Consensus Classification (2022) where they differ), and if it departs from it, why?
   Why: Departures from guidelines are sometimes right for an individual; they should be explained.
5. For my situation (making the diagnosis on the fluid), which of the standard options do you recommend and why?
   Why: Guideline options include: The effusion is drained and sent, fresh, for cytology, flow cytometry and immunohistochemistry. The diagnosis requires the Kaposi sarcoma herpesvirus latency-associated nuclear antigen in the tumour nuclei. A cavity lymphoma without the virus is a different disease, recognised separately in 2022, that arises in fluid overload from heart failure, kidney failure or cirrhosis and behaves better. HIV testing is part of the work-up in every case.

Add these to your appointment list, or take the full question set for this cancer.

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

1. Between Cyclophosphamide, Doxorubicin and Etoposide, which do you recommend for me, and what about my case would make you choose differently?
   Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
   Why: The aim shapes how much side effect and disruption is worth accepting.
3. What happens if I delay, or decline this step for now? Is the decision reversible?
   Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
4. Does your recommendation follow the current guideline (NCI PDQ: adult non-Hodgkin lymphoma treatment), and if it departs from it, why?
   Why: Departures from guidelines are sometimes right for an individual; they should be explained.
5. For my situation (treatment), which of the standard options do you recommend and why?
   Why: Guideline options include: Combination chemotherapy, with antiretroviral therapy started or optimised at the same time where there is HIV, because controlling the HIV is part of controlling the lymphoma. Anti-CD20 antibodies have no role: the cells do not carry CD20. There has never been a randomised trial in this entity and the regimens come from series and from the HIV-associated lymphoma literature; they sit in the treatment layer of this family and on the HIV-associated lymphoma page. Entry into a trial is a reasonable first choice rather than a last resort.
6. Am I a candidate for Cyclophosphamide, Doxorubicin, Etoposide, and what side effects should I expect?
   Why: Knowing the expected toxicities helps you plan work, family, and supportive care.

Add these to your appointment list, or take the full question set for this cancer.